Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.
Dr. Chorny's research program focuses on nanomedicines as well as drug, cell, and gene delivery systems for treating proliferative disease. His current research specifically focuses on the use of nanoparticle-mediated delivery to solid tumors and site-specific delivery for cardiovascular disease.
CHOP has long investigated biodegradable nanoparticles for medical use. With diameters ranging from a few tens to a few hundreds of nanometers, these particles are 10 to 1000 times smaller than red blood cells.
As part of its mission to find "a cure for all children with cancer," Alex's Lemonade Stand Foundation recently announced more than $7 million in new grants to researchers around the country, including four at The Children's Hospital of Philadelphia. Children's Hospital investigators Garrett Brodeur, MD, Michael Hogarty, MD, Richard Aplenc, MD, and Robert Schnepp, MD, PhD, all received grants from the organization, for a total of $800,000 in cancer research funding.
A pediatric oncologist with the Cancer Center at The Children’s Hospital of Philadelphia recently received a national award highlighting his lifetime research on neuroblastoma, the most common solid tumor of childhood. The American Society of Clinical Oncology conferred one of its highest awards on Garrett M. Brodeur, MD, who was given the Pediatric Oncology Award and delivered the Pediatric Oncology Lecture.
Research in the Brodeur Lab focuses on two main areas: nanoparticle drug delivery and cancer predisposition. Nanomedicines allow the delivery of much more drug to the tumor and much less to the patient. The lab is also interested in identifying novel cancer predisposition genes as well as developing enhanced surveillance techniques to identify cancer early in predisposed individuals, improve outcomes, and reduce side effects.